Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.29
DYAX's Cash to Debt is ranked higher than
60% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. DYAX: 2.29 )
DYAX' s 10-Year Cash to Debt Range
Min: 0.27   Max: No Debt
Current: 2.29

Equity to Asset 0.50
DYAX's Equity to Asset is ranked higher than
63% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. DYAX: 0.50 )
DYAX' s 10-Year Equity to Asset Range
Min: -1.26   Max: 0.82
Current: 0.5

-1.26
0.82
F-Score: 5
Z-Score: 9.33
M-Score: -2.58
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -1.14
DYAX's Operating margin (%) is ranked higher than
83% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. DYAX: -1.14 )
DYAX' s 10-Year Operating margin (%) Range
Min: -389.57   Max: -27.65
Current: -1.14

-389.57
-27.65
Net-margin (%) -15.92
DYAX's Net-margin (%) is ranked higher than
80% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. DYAX: -15.92 )
DYAX' s 10-Year Net-margin (%) Range
Min: -393.89   Max: -44
Current: -15.92

-393.89
-44
ROE (%) -19.33
DYAX's ROE (%) is ranked higher than
78% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. DYAX: -19.33 )
DYAX' s 10-Year ROE (%) Range
Min: -1406.43   Max: -22.89
Current: -19.33

-1406.43
-22.89
ROA (%) -6.93
DYAX's ROA (%) is ranked higher than
82% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. DYAX: -6.93 )
DYAX' s 10-Year ROA (%) Range
Min: -89.25   Max: -10.22
Current: -6.93

-89.25
-10.22
ROC (Joel Greenblatt) (%) -16.95
DYAX's ROC (Joel Greenblatt) (%) is ranked higher than
83% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. DYAX: -16.95 )
DYAX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1121.26   Max: -183.67
Current: -16.95

-1121.26
-183.67
Revenue Growth (%) -3.10
DYAX's Revenue Growth (%) is ranked higher than
76% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. DYAX: -3.10 )
DYAX' s 10-Year Revenue Growth (%) Range
Min: -37.4   Max: 21.1
Current: -3.1

-37.4
21.1
EBITDA Growth (%) 7.70
DYAX's EBITDA Growth (%) is ranked higher than
84% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. DYAX: 7.70 )
DYAX' s 10-Year EBITDA Growth (%) Range
Min: -49.1   Max: 10.4
Current: 7.7

-49.1
10.4
» DYAX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

DYAX Guru Trades in Q4 2013

Paul Tudor Jones 54,343 sh (New)
Jim Simons 528,000 sh (+459.32%)
PRIMECAP Management 11,806,990 sh (+8.25%)
Chuck Royce 809,000 sh (-23.61%)
» More
Q1 2014

DYAX Guru Trades in Q1 2014

Louis Moore Bacon 75,000 sh (New)
Steven Cohen 960,155 sh (New)
Jim Simons 742,804 sh (+40.68%)
PRIMECAP Management 11,806,990 sh (unchged)
Chuck Royce 485,600 sh (-39.98%)
Paul Tudor Jones 16,099 sh (-70.38%)
» More
Q2 2014

DYAX Guru Trades in Q2 2014

Joel Greenblatt 46,505 sh (New)
Steven Cohen 44,100 sh (unchged)
Louis Moore Bacon Sold Out
Paul Tudor Jones Sold Out
PRIMECAP Management 11,129,830 sh (-5.74%)
Chuck Royce 380,200 sh (-21.71%)
Jim Simons 469,186 sh (-36.84%)
» More
Q3 2014

DYAX Guru Trades in Q3 2014

Paul Tudor Jones 17,323 sh (New)
Steven Cohen 56,500 sh (+28.12%)
Jim Simons Sold Out
PRIMECAP Management 10,884,960 sh (-2.2%)
Joel Greenblatt 44,152 sh (-5.06%)
Chuck Royce 244,900 sh (-35.59%)
» More
» Details

Insider Trades

Latest Guru Trades with DYAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-06-30 New Buy0.01%$6.11 - $9.96 $ 15.0598%46505
PRIMECAP Management 2013-06-30 Add 24.89%0.01%$2.29 - $4.42 $ 15.05362%10906810
PRIMECAP Management 2012-09-30 New Buy0.04%$2.13 - $2.75 $ 15.05507%8732900
PRIMECAP Management 2012-06-30 Sold Out 0.02%$1.48 - $2.19 $ 15.05765%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 19.50
DYAX's P/B is ranked higher than
60% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. DYAX: 19.50 )
DYAX' s 10-Year P/B Range
Min: 2.05   Max: 74.67
Current: 19.5

2.05
74.67
P/S 27.30
DYAX's P/S is ranked higher than
74% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. DYAX: 27.30 )
DYAX' s 10-Year P/S Range
Min: 2.46   Max: 27.3
Current: 27.3

2.46
27.3
EV-to-EBIT -2354.74
DYAX's EV-to-EBIT is ranked higher than
80% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. DYAX: -2354.74 )
DYAX' s 10-Year EV-to-EBIT Range
Min: -2273   Max: -2
Current: -2354.74

-2273
-2
Current Ratio 11.60
DYAX's Current Ratio is ranked higher than
89% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. DYAX: 11.60 )
DYAX' s 10-Year Current Ratio Range
Min: 1.34   Max: 13.3
Current: 11.6

1.34
13.3
Quick Ratio 11.37
DYAX's Quick Ratio is ranked higher than
89% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. DYAX: 11.37 )
DYAX' s 10-Year Quick Ratio Range
Min: 1.34   Max: 13.1
Current: 11.37

1.34
13.1

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.10
DYAX's Price/Net Cash is ranked higher than
76% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. DYAX: 25.10 )
DYAX' s 10-Year Price/Net Cash Range
Min: 3.14   Max: 251.17
Current: 25.1

3.14
251.17
Price/Net Current Asset Value 23.50
DYAX's Price/Net Current Asset Value is ranked higher than
75% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. DYAX: 23.50 )
DYAX' s 10-Year Price/Net Current Asset Value Range
Min: 2.76   Max: 237
Current: 23.5

2.76
237
Price/Tangible Book 19.50
DYAX's Price/Tangible Book is ranked higher than
65% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. DYAX: 19.50 )
DYAX' s 10-Year Price/Tangible Book Range
Min: 1.05   Max: 72
Current: 19.5

1.05
72
Price/Median PS Value 3.40
DYAX's Price/Median PS Value is ranked higher than
71% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. DYAX: 3.40 )
DYAX' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 4.08
Current: 3.4

0.14
4.08

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DY8.Germany,
Dyax Corp was incorporated in the state of Delaware in the year 1989, and merged with Protein Engineering Corporation in 1995. It is a biopharmaceutical company focused on Hereditary Angioedema and Other Plasma-Kallikrein-Mediated Disorders and Licensing and Funded Research Portfolio. The Company develops and commercializes treatments for hereditary angioedema and to identify other disorders that are mediated by plasma kallikrein. It is engaged in identifying and developing treatments for patients who experience PKM angioedema. Plasma kallikrein, an enzyme found in blood, produces bradykinin, a protein that causes blood vessels to enlarge or dilate, which can cause swelling known as angioedema. Excess plasma kallikrein activity plays a role in HAE and could potentially play a role in a number of inflammatory diseases, including Crohn's disease, psoriasis, rheumatoid arthritis, and various mast cell disorders. It also develops KALBITOR for the treatment of acute attacks of HAE. KALBITOR is currently distributed through a limited network of wholesale, hospital and specialty pharmacy arrangements. Its portfolio of product candidates being developed by licensees using its phage display technology. For KALBITOR as a treatment for HAE, its competitors include: Manufacturers of corticosteroids. Other competitors for the treatment of HAE are companies that are developing small molecule plasma kallikrein inhibitors. The preclinical study and clinical testing, manufacture, labeling, storage, record keeping, advertising, promotion, export, and marketing, among other things, of its products and product candidates, including KALBITOR and those of its licensees, are subject to extensive regulation by governmental authorities in the United States and other countries.
» More Articles for NAS:DYAX

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight: DYAX, IBI, FARM, TAP, DBM Mar 19 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 10,000 Shares Mar 15 2011 
Dyax Corp. Reports Operating Results (10-K) Mar 02 2011 
Dyax Corp. Reports Operating Results (10-Q) Nov 02 2010 
Dyax Corp. (DYAX) CEO Gustav Christensen buys 5,000 Shares Sep 15 2010 
Dyax Corp. (DYAX) CFO George V Migausky buys 12,000 Shares Aug 25 2010 
Weekly CFO Buys Highlight: Apollo Investment Corp., Dyax Corp., Heska Corp., Vaughan Foods Inc., Wir Jun 05 2010 
Weekly CFO Buy Highlights: F.N.B. Corp, Great Wolf Resorts Inc, Dyax Corp, Transcat Inc, Cal Dive In Jun 20 2009 
Dyax Corp. (DYAX) CFO George V Migausky buys 9,000 Shares Jun 16 2009 

More From Other Websites
Can Dyax (DYAX) Keep the Earnings Streak Alive This Quarter? Dec 10 2014
Dyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare Conference Dec 03 2014
Dyax Corp. to Participate in the 25th Annual Oppenheimer Healthcare Conference Dec 03 2014
Strong On High Relative Volume: Dyax (DYAX) Nov 24 2014
Dyax Corp. Recognized as a "Top Place to Work" by The Boston Globe Nov 18 2014
Dyax Corp. Recognized as a “Top Place to Work” by The Boston Globe Nov 18 2014
Why Dyax (DYAX) Could Be Positioned for a Surge? Nov 07 2014
10-Q for Dyax Corp. Nov 05 2014
Can Dyax (DYAX) Stock Continue to Grow Earnings? Nov 04 2014
DYAX CORP Files SEC form 10-Q, Quarterly Report Nov 03 2014
Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930 Nov 03 2014
Dyax Corp. Announces Expansion of Phase 1b Clinical Trial for DX-2930 Nov 03 2014
Will Dyax (DYAX) Continue to Surge Higher? Oct 30 2014
Dyax beats Street 3Q forecasts Oct 28 2014
Dyax beats Street 3Q forecasts Oct 28 2014
Dyax Corp. Announces Third Quarter 2014 Financial Results Oct 28 2014
DYAX CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Oct 28 2014
Dyax Corp. Announces Third Quarter 2014 Financial Results Oct 28 2014
Q3 2014 Dyax Corp Earnings Release - Time Not Supplied Oct 28 2014
Dyax Corp. to Host Third Quarter 2014 Earnings Call and Webcast Oct 14 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK